TNO and Demcon have announced plans for a new joint venture aimed at bringing advanced technology for deformable mirrors to the global market.

Curix, part of the Demcon group, today announced that the SEISMIC research consortium, coordinated by Philips, together with the Erasmus MC as academic lead, has been awarded funding from the Innovative Health Initiative (IHI) to transform neurosurgery through the seamless integration of minimally invasive surgical techniques and advanced imaging technologies. The EUR 23.5 million public funding will be complemented by EUR 14.9 million in in-kind contributions and additional resources from industry partners, supporting a five-year research and innovation program that also includes eight clinical studies.

Technology developer and producer Demcon further expands its technological capabilities with the introduction of Leap Development into the Demcon group. The company will continue its activities under the banner of Demcon electronics. The Deventer-based organization specializes in RF technology, wireless communication, embedded systems and integrated electronics development. With this latest addition, the Demcon group now has a specialized company that is dedicated entirely to electronics development projects and has state-of-the-art testing facilities.

Curix, part of the Demcon group, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology. With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer's and Parkinson's disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix.